Back to Journals » OncoTargets and Therapy » Volume 10

The role of KPNβ1 in neuro-oncology

Authors Lilley M, Farassati F

Received 6 March 2017

Accepted for publication 6 March 2017

Published 10 April 2017 Volume 2017:10 Pages 2067—2068

DOI https://doi.org/10.2147/OTT.S136247

Checked for plagiarism Yes

Megan Lilley,1,2 Faris Farassati1,3

1Midwest Biomedical Research Foundation, Kansas City Veterans Affairs Medical Center, 2School of Medicine, University of Missouri, 3Saint Luke’s Cancer Institute–Saint Luke’s Marion Bloch Neuroscience Institute, Kansas City, MO, USA

KPNβ1, also known as importin-β, is part of the karyopherin superfamily of nuclear transport proteins.1 The classical importin-α/β system is believed to import up to half of the nuclear traffic.2 Importins and exportins transport pro-oncogenic mediators across the nuclear membrane and are found to be overexpressed in a number of cancer types, including breast, colon, esophageal, gastric, lung, lymphoma, melanoma, pancreatic, and prostate cancer.3 The nuclear pore complex (NPC) is composed of approximately 30 proteins (nucleoporins) that are arranged octagonally around a central channel. KPNβ1 participates in the classical nuclear import pathway alongside its adaptor protein – importin-α. Importin-α first recognizes and binds the cytoplasmic cargo via its nuclear localization signals, and then associates with importin-β via the importin-β binding (IBB) domain. This complex (nuclear localization signals–importin-α–importin-β) then traverses the nuclear pore complex.4 This active transport is able to occur against the concentration gradient, due to varying levels of Ran, a GTPase.4

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Ezh2, a novel target in detection and therapy of breast cancer

Pourakbar S, Pluard TJ, Accurso AD, Farassati F

OncoTargets and Therapy 2017, 10:2685-2687

Published Date: 22 May 2017

Editorial announcing PubMed indexing of Oncolytic Virotherapy

Farassati F

Oncolytic Virotherapy 2017, 6:19-20

Published Date: 15 February 2017